Identifier
Created
Classification
Origin
03ABUDHABI144
2003-01-12 06:46:00
CONFIDENTIAL
Embassy Abu Dhabi
Cable title:
UAE HEALTH MINISTRY REJECTS THE MANDATORY
null Diana T Fritz 06/05/2007 04:19:03 PM From DB/Inbox: Search Results Cable Text: CONFIDENTIAL SIPDIS TELEGRAM January 12, 2003 To: No Action Addressee Action: Unknown From: AMEMBASSY ABU DHABI (ABU DHABI 144 - ROUTINE) TAGS: PREL, ETRD, KIPR Captions: None Subject: UAE HEALTH MINISTRY REJECTS THE MANDATORY REGISTRATION OF PHARMACEUTICALS BY THE GCC Ref: None _________________________________________________________________ C O N F I D E N T I A L ABU DHABI 00144 SIPDIS CXABU: ACTION: ECON INFO: P/M AMB DCM POL Laser1: INFO: FCS DISSEMINATION: ECON CHARGE: PROG APPROVED: A/DCM:TWILLIAMS DRAFTED: ECON:CMCRUMPLER CLEARED: NONE VZCZCADI589 RR RUEHC RUEHGV RUCNWTO RUCPDOC RUEHRH RUEHDE DE RUEHAD #0144 0120646 ZNY CCCCC ZZH R 120646Z JAN 03 FM AMEMBASSY ABU DHABI TO RUEHC/SECSTATE WASHDC 7820 INFO RUEHGV/USMISSION GENEVA 0498 RUCNWTO/WORLD TRADE ORGANIZATION COLLECTIVE RUCPDOC/USDOC WASHDC RUEHRH/AMEMBASSY RIYADH 1207 RUEHDE/AMCONSUL DUBAI 2682
C O N F I D E N T I A L ABU DHABI 000144
SIPDIS
STATE FOR NEA/ARP, NEA/PPR AND EB/TPP/MTA/IPC
STATE PASS USTR - KALVAREZ AND JBUNTIN
USDOC FOR USPTO
USDOC FOR 4250/DOC/MAC/ONE/GUGLIELMI
GENEVA PASS USTR
E.O. 12958: DECL: 1/11/2007
TAGS: PREL KIPR ETRD TC
SUBJECT: UAE HEALTH MINISTRY REJECTS THE MANDATORY
REGISTRATION OF PHARMACEUTICALS BY THE GCC
C O N F I D E N T I A L ABU DHABI 000144
SIPDIS
STATE FOR NEA/ARP, NEA/PPR AND EB/TPP/MTA/IPC
STATE PASS USTR - KALVAREZ AND JBUNTIN
USDOC FOR USPTO
USDOC FOR 4250/DOC/MAC/ONE/GUGLIELMI
GENEVA PASS USTR
E.O. 12958: DECL: 1/11/2007
TAGS: PREL KIPR ETRD TC
SUBJECT: UAE HEALTH MINISTRY REJECTS THE MANDATORY
REGISTRATION OF PHARMACEUTICALS BY THE GCC
1. (U) Classified by Acting DCM Thomas E. Williams for
reasons 1.5 (b) and (d).
2. (C) Summary and comment: UAE Ministry of Health Director
of Drug Control Department Dr. Easa Al-Mansouri provided
Econoff a read-out on January 11 of the GCC Health Ministers
Conference last week in Abu Dhabi. The ministers discussed
a variety of issues, including the impact of international
trade agreements on the development of a regional
pharmaceutical industry. Al-Mansouri assured Econoff that
the UAE, along with the smaller Gulf countries, is standing
firm against Saudi pressure to mandate registration of
pharmaceuticals through the GCC Patent Office in Riyadh.
The UAEG is well aware that caving on this issue would
probably cause it to contravene its WTO obligations. End
summary and comment.
3. (C) The registration of drugs in the region was the most
controversial item on the conference agenda, according to
Al-Mansouri. The Saudis apparently are eager to make
compulsory the registration of all pharmaceuticals through
the GCC Patent Office in Riyadh. Al-Mansouri noted that the
other GCC Ministers refused Riyadh's request because of
differences between Saudi and the rest-of-Gulf levels of IPR
protection. Al-Mansouri admitted that companies would
benefit by registering a product one time for six countries,
but noted that "no American company would be so stupid" to
expect that UAE levels of protection, for example, would
extend to Saudi Arabia through the GCC registration
mechanism.
4. (C) The ministers also debated the unification of drug
prices throughout the GCC. According to Al-Mansouri, most
local manufacturers of generics are permitted to charge
consumers 70-80 percent of the market price of the
innovative product. Prices of pharmaceuticals produced in
Saudi Arabia, however, are much higher. Currently, the GCC
registers only Arab generics -- locally manufactured
products -- but will begin registration of innovative
products this year. "This is the plan," said Al-Mansouri,
"but its success depends on Saudi Arabia joining the WTO and
getting serious about patent protection for
pharmaceuticals."
5. (C) As an aside, Al-Mansouri confirmed that a total of
four local pharmaceutical manufacturers would be operational
in the UAE by the end of 2003 -- Julphar in Ras Al Khaimah,
GlobalPharm in Dubai, and one each in Abu Dhabi and Sharjah.
Al-Mansouri noted that all factories would produce garden-
variety generic antibiotics or repackage imported drugs for
the local market.
Wahba
SIPDIS
STATE FOR NEA/ARP, NEA/PPR AND EB/TPP/MTA/IPC
STATE PASS USTR - KALVAREZ AND JBUNTIN
USDOC FOR USPTO
USDOC FOR 4250/DOC/MAC/ONE/GUGLIELMI
GENEVA PASS USTR
E.O. 12958: DECL: 1/11/2007
TAGS: PREL KIPR ETRD TC
SUBJECT: UAE HEALTH MINISTRY REJECTS THE MANDATORY
REGISTRATION OF PHARMACEUTICALS BY THE GCC
1. (U) Classified by Acting DCM Thomas E. Williams for
reasons 1.5 (b) and (d).
2. (C) Summary and comment: UAE Ministry of Health Director
of Drug Control Department Dr. Easa Al-Mansouri provided
Econoff a read-out on January 11 of the GCC Health Ministers
Conference last week in Abu Dhabi. The ministers discussed
a variety of issues, including the impact of international
trade agreements on the development of a regional
pharmaceutical industry. Al-Mansouri assured Econoff that
the UAE, along with the smaller Gulf countries, is standing
firm against Saudi pressure to mandate registration of
pharmaceuticals through the GCC Patent Office in Riyadh.
The UAEG is well aware that caving on this issue would
probably cause it to contravene its WTO obligations. End
summary and comment.
3. (C) The registration of drugs in the region was the most
controversial item on the conference agenda, according to
Al-Mansouri. The Saudis apparently are eager to make
compulsory the registration of all pharmaceuticals through
the GCC Patent Office in Riyadh. Al-Mansouri noted that the
other GCC Ministers refused Riyadh's request because of
differences between Saudi and the rest-of-Gulf levels of IPR
protection. Al-Mansouri admitted that companies would
benefit by registering a product one time for six countries,
but noted that "no American company would be so stupid" to
expect that UAE levels of protection, for example, would
extend to Saudi Arabia through the GCC registration
mechanism.
4. (C) The ministers also debated the unification of drug
prices throughout the GCC. According to Al-Mansouri, most
local manufacturers of generics are permitted to charge
consumers 70-80 percent of the market price of the
innovative product. Prices of pharmaceuticals produced in
Saudi Arabia, however, are much higher. Currently, the GCC
registers only Arab generics -- locally manufactured
products -- but will begin registration of innovative
products this year. "This is the plan," said Al-Mansouri,
"but its success depends on Saudi Arabia joining the WTO and
getting serious about patent protection for
pharmaceuticals."
5. (C) As an aside, Al-Mansouri confirmed that a total of
four local pharmaceutical manufacturers would be operational
in the UAE by the end of 2003 -- Julphar in Ras Al Khaimah,
GlobalPharm in Dubai, and one each in Abu Dhabi and Sharjah.
Al-Mansouri noted that all factories would produce garden-
variety generic antibiotics or repackage imported drugs for
the local market.
Wahba